VivoSim Labs, INC. SEC filings VIVS
VivoSim Labs, INC. has 819 filings in SEC EDGAR's recent list, going back to Aug 4, 2010. Its latest annual report, Form ARS, was filed on Aug 21, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (material agreement). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Aug 21, 2026 | Sep 30, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 10, 2026 | Sep 30, 2026 |
| DEFA14A | Additional proxy material | Nov 3, 2025 | — |
| DEF 14A | Proxy statement | Nov 3, 2025 | Dec 16, 2025 |
| DEFA14A | Additional proxy material | Oct 7, 2024 | — |
| DEF 14A | Proxy statement | Oct 7, 2024 | Oct 4, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 18, 2024 | Sep 18, 2024 |
| DEF 14A | Proxy statement | Sep 13, 2023 | Oct 31, 2023 |
| DEFA14A | Additional proxy material | Sep 13, 2023 | — |
| PRE 14A | Preliminary proxy statement | Jul 14, 2023 | Sep 14, 2023 |
| DEFA14A | Additional proxy material | Sep 22, 2022 | — |
| DEFA14A | Additional proxy material | Jul 26, 2022 | — |
| DEF 14A | Proxy statement | Jul 26, 2022 | Sep 7, 2022 |
| DEFA14A | Additional proxy material | Sep 17, 2021 | — |
| DEFA14A | Additional proxy material | Aug 31, 2021 | — |
| DEFA14A | Additional proxy material | Aug 5, 2021 | — |
| DEF 14A | Proxy statement | Aug 5, 2021 | Sep 14, 2021 |
| DEFA14A | Additional proxy material | Sep 3, 2020 | — |
| DEFA14A | Additional proxy material | Aug 17, 2020 | — |
| DEFA14A | Additional proxy material | Aug 6, 2020 | — |
| DEF 14A | Proxy statement | Aug 6, 2020 | Sep 15, 2020 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2020 | Jul 24, 2020 |
| DEFA14A | Additional proxy material | Jul 15, 2020 | — |
| DEFA14A | Additional proxy material | Aug 7, 2019 | — |
| DEFA14A | Additional proxy material | Jul 26, 2019 | — |
| DEF 14A | Proxy statement | Jul 26, 2019 | Sep 5, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 9, 2019 | Sep 5, 2019 |
| DEFA14A | Additional proxy material | Jun 15, 2018 | — |
| DEF 14A | Proxy statement | Jun 15, 2018 | Jul 26, 2018 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2018 | Jul 26, 2018 |
| DEFA14A | Additional proxy material | Jul 14, 2017 | — |
| DEF 14A | Proxy statement | Jul 14, 2017 | Aug 24, 2017 |
| DEFA14A | Additional proxy material | Jul 8, 2016 | — |
| DEF 14A | Proxy statement | Jul 8, 2016 | Aug 17, 2016 |
| DEFA14A | Additional proxy material | Jul 10, 2015 | — |
| DEF 14A | Proxy statement | Jul 10, 2015 | Aug 20, 2015 |
| DEFA14A | Additional proxy material | Jul 11, 2014 | — |
| DEF 14A | Proxy statement | Jul 11, 2014 | Aug 20, 2014 |
| DEFA14A | Additional proxy material | Jul 12, 2013 | — |
| DEF 14A | Proxy statement | Jul 12, 2013 | Aug 21, 2013 |
| DEF 14A | Proxy statement | Sep 17, 2012 | Oct 17, 2012 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIVS (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1497253
- Former names
- ORGANOVO HOLDINGS, INC. (until Apr 23, 2025); REAL ESTATE RESTORATION & RENTAL, INC. (until Oct 31, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.